Online inquiry

IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5184MR)

This product GTTS-WQ5184MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL13 gene. The antibody can be applied in Idiopathic pulmonary fibrosis research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001354991.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3596
UniProt ID P35225
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ5184MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10800MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA M777-16-3
GTTS-WQ9818MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA JS004
GTTS-WQ10474MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY2541546
GTTS-WQ741MR IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AAB-001
GTTS-WQ14499MR IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA RYI-018
GTTS-WQ13063MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ5334MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CD20-TCB (2:1)
GTTS-WQ11876MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MLN-0264
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW